Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes

Hongliang Duan; Mengmeng Ning; Qingan Zou; Yangliang Ye; Ying Feng; Lina Zhang; Ying Leng; Jianhua Shen

doi:10.1021/jm500829b

Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes

Hongliang Duan, Mengmeng Ning, Qingan Zou, Yangliang Ye, Ying Feng, Lina Zhang, Ying Leng, Jianhua Shen

CAS - Shanghai Institute of Materia Medica

Research output: Contribution to journal › Article › peer-review

79 Citations (Scopus)

Abstract

Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 Å², and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.

Original language	English
Pages (from-to)	3315-3328
Number of pages	14
Journal	Journal of Medicinal Chemistry
Volume	58
Issue number	8
DOIs	https://doi.org/10.1021/jm500829b
Publication status	Published - 23 Apr 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/jm500829b

Cite this

@article{b6f35c068dcf4c1dbd7a64840a593604,

title = "Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes",

abstract = "Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 {\AA}2, and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.",

author = "Hongliang Duan and Mengmeng Ning and Qingan Zou and Yangliang Ye and Ying Feng and Lina Zhang and Ying Leng and Jianhua Shen",

note = "Publisher Copyright: {\textcopyright} 2015 American Chemical Society.",

year = "2015",

month = apr,

day = "23",

doi = "10.1021/jm500829b",

language = "English",

volume = "58",

pages = "3315--3328",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "8",

}

TY - JOUR

T1 - Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes

AU - Duan, Hongliang

AU - Ning, Mengmeng

AU - Zou, Qingan

AU - Ye, Yangliang

AU - Feng, Ying

AU - Zhang, Lina

AU - Leng, Ying

AU - Shen, Jianhua

PY - 2015/4/23

Y1 - 2015/4/23

N2 - Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 Å2, and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.

AB - Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 Å2, and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.

UR - http://www.scopus.com/inward/record.url?scp=84928501244&partnerID=8YFLogxK

U2 - 10.1021/jm500829b

DO - 10.1021/jm500829b

M3 - Article

C2 - 25710631

AN - SCOPUS:84928501244

SN - 0022-2623

VL - 58

SP - 3315

EP - 3328

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 8

ER -

Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this